NVO
BuyUnloved QualityAI neutralNovo Nordisk A/S · Healthcare · Denmark · $168.6B cap · $510.1M/day traded
$38.58 -0.2% · close 12 Oct · scored 14 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Read our full research report on NVO (Apr 2026), freeReport expected 4 Nov: the next-year EPS estimate has risen 2.1% over the last 13 weeks.
As of 14 Oct 2026, MoatMap's StockRank for Novo Nordisk A/S (NVO) is 78/100, ranked against 24,000+ stocks in 35 markets (Quality 75, Value 60, Momentum 38, each scored against its sector).
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Novo Nordisk remains one of the two leaders in GLP-1 treatments for diabetes and obesity, with strong quality scores and a much lower valuation than a year ago. It continues to publish data defending Ozempic and Wegovy, but Eli Lilly's higher-dose Zepbound and oral drug are widening the competitive gap, and forward estimates fell 2.1% over the past month.
ABOUT NOVO NORDISK A/S
Read
Novo Nordisk A/S is a global healthcare company with a leading position in diabetes care, obesity, and other serious chronic diseases, renowned for its innovative pharmaceutical products like Ozempic and Wegovy. Its competitive moat is built on extensive R&D, strong patent protection, a global distribution network, and decades of specialization in metabolic disorders. Novo Nordisk is a market leader in diabetes and obesity pharmaceuticals, driven by continuous innovation and expanding therapeutic areas.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 26.5B | 34.8B | 43.5B | 46.3B | 20.4% | 49.4B | 45.0B | 45.6B | -0.7% |
| EPS | 1.83 | 2.79 | 3.39 | 3.45 | 23.4% | 4.09 | 3.38 | 3.31 | -2.1% |
| Shares | 4.5B | 4.5B | 4.4B | 4.4B | -1.3% | 3.3B | — | — | — |
| Debt | 3.9B | 4.0B | 15.4B | 19.6B | 71.9% | 21.0B | — | — | — |
| Equity | 12.5B | 15.9B | 21.5B | 29.0B | 32.5% | — | — | — | — |
| Op CF | 11.8B | 16.3B | 18.1B | 17.8B | 14.7% | 19.8B | — | — | — |
| Inv CF | -3.7B | -6.6B | -19.3B | -11.8B | — | — | — | — | — |
| Fin CF | -7.8B | -9.5B | 1.3B | -4.3B | — | — | — | — | — |
No new 52-week low for 30 weeks, 13% above that low, but not back above a rising 50-day average.
Swung more than 57% of stocks we rank over the past year (46% a year).
How this is worked out
StockRank judges the business. The price check reads only the chart: it is the price side of the Momentum score, in words.
The rules: Still falling is a new 52-week low in the last two weeks, at least 25% below the high. Finding a floor is no new low since. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average and within 15% of the high.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn like this one cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of NVO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| NVO | Novo Nordisk A/S(you) | $168.6B | 78 | Buy |
| GIS.DE | Gilead Sciences, Inc. | $185.7B | 79 | Buy |
| AZN | AstraZeneca PLC | $253.3B | 76 | Buy |
| PFE | Pfizer Inc. | $160.6B | 88 | Strong Buy |
| NVS | Novartis AG | $271.3B | 80 | Strong Buy |
| GSK | GSK plc | $99.6B | 81 | Strong Buy |
| MRCK34.SA | Merck & Co., Inc. | $360.4B | 78 | Buy |
| AMGN | Amgen Inc. | $219.5B | 91 | Strong Buy |
| BAYN.DE | Bayer Aktiengesellschaft | $55.2B | 79 | Buy |
| SNY | Sanofi | $99.8B | 91 | Strong Buy |
Peer medians: ROE 2.9% · P/E 24.0x · Gross margin 53.8%
Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.